请输入您要查询的百科知识：

　

词条 Primary biliary cholangitis
释义

  1. Signs and symptoms

  2. Causes

  3. Diagnosis

     Liver biopsy  Histopathology stages 

  4. Treatment

  5. Prognosis

  6. Epidemiology

  7. History

  8. Society and culture

     Support groups  PBC Foundation  PBCers Organization  Name 

  9. References

  10. External links

{{Infobox medical condition (new)
| name = Primary biliary cholangitis
| image = Primary biliary cirrhosis intermed mag much cropping.jpg
| caption = Micrograph of PBC showing bile duct inflammation and injury. H&E stain.
| pronounce =
| field = Gastroenterology
| synonyms = Primary biliary cirrhosis
| symptoms = Cholestasis, pruritus, fatigue
| complications = Cirrhosis, hepatic failure, portal hypertension
| onset = Usually middle-aged women
| duration =
| types =
| causes = Autoimmune
| risks =
| diagnosis = Anti-mitochondrial antibodies, liver biopsy
| differential =
| prevention =
| treatment =
| medication =
| prognosis =
| frequency =
| deaths =
}}

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.[1][2][3] It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. Further slow damage to the liver tissue can lead to scarring, fibrosis, and eventually cirrhosis.

Common symptoms are tiredness, itching and, in more advanced cases, jaundice. In early cases, there may only be changes in blood tests.[4]

PBC is a relatively rare disease, affecting up to 1 in 3–4,000 people.[4][5] It is much more common in women, with a sex ratio of at least 9:1 female to male.[1]

The condition has been recognised since at least 1851 and was named "primary biliary cirrhosis" in 1949.[6] Because cirrhosis is a feature only of advanced disease, a change of its name to "primary biliary cholangitis" was proposed by patient advocacy groups in 2014.[7][8]

{{TOC limit|3}}

Signs and symptoms

People with PBC experience fatigue (80 percent) that leads to sleepiness during the daytime; more than half of those have severe fatigue. Dry skin and dry eyes are also common. Itching (pruritus) occurs in 20–70 percent.[4] People with more severe PBC may have jaundice (yellowing of the eyes and skin).[9] PBC impairs bone density and there is an increased risk of fracture.[9] Xanthelasma (skin lesions around the eyes) or other xanthoma may be present as a result of increased cholesterol levels.[10]

PBC can eventually progress to cirrhosis of the liver. This in turn may lead to a number of symptoms or complications:

  • Fluid retention in the abdomen (ascites) in more advanced disease
  • Enlarged spleen in more advanced disease
  • Oesophageal varices in more advanced disease
  • Hepatic encephalopathy, including coma in extreme cases in more advanced disease.

People with PBC may also sometimes have the findings of an associated extrahepatic autoimmune disorder such as rheumatoid arthritis or Sjögren's syndrome (in up to 80 percent of cases).[10][16]

Causes

PBC has an immunological basis, and is classified as an autoimmune disorder.[11] It results from a slow, progressive destruction of the small bile ducts of the liver, with the intralobular ducts and the Canals of Hering (intrahepatic ductules) being affected early in the disease.[12] This progresses to the development of fibrosis, cholestasis and, in some people, cirrhosis.[2]

Most people with PBC (>90 percent) have anti-mitochondrial antibodies (AMAs) against pyruvate dehydrogenase complex (PDC-E2), an enzyme complex that is found in the mitochondria.[1] People who are negative for AMAs are usually found to be positive when more sensitive methods of detection are used.[13]

People with PBC may also have been diagnosed with another autoimmune disease, such as a rheumatological, endocrinological, gastrointestinal, pulmonary, or dermatological condition, suggesting shared genetic and immune abnormalities.[14]

Common associations include Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis, lupus, hypothyroidism and gluten sensitive enteropathy.[14][15][16][17]

A genetic predisposition to disease has been thought to be important for some time. Evidence for this includes cases of PBC in family members, identical twins both having the condition (concordance), and clustering of PBC with other autoimmune diseases.[11] In 2009, a Canadian-led group of investigators reported in the New England Journal of Medicine results from the first PBC genome-wide association study.[18][19] This research revealed parts of the IL12 signaling cascade, particularly IL12A and IL12RB2 polymorphisms, to be important in the aetiology of the disease in addition to the HLA region. In 2012, two independent PBC association studies increased the total number of genomic regions associated to 26, implicating many genes involved in cytokine regulation such as TYK2, SH2B3 and TNFSF11.[20][21]

A study of over 2000 patients identified a gene - POGLUT1 - that appeared to be associated with this condition.[22]Earlier studies have also suggested that this gene may be involved. The implicated protein is an endoplasmic reticulum O-glucosyltransferase.

An environmental Gram negative alphabacterium — Novosphingobium aromaticivorans[23] has been associated with this disease with several reports suggesting an aetiological role for this organism.[24][25][26] The mechanism appears to be a cross reaction between the proteins of the bacterium and the mitochondrial proteins of the liver cells.[27] The gene encoding CD101 may also play a role in host susceptibility to this disease.[28]

There is a failure of immune tolerance against the mitochondrial pyruvate dehydrogenase complex (PDC-E2),[2] and this may also be the case with other proteins, including the gp210 and p62 nuclear pore proteins. Gp210 has increased expression in the bile duct of anti-gp210 positive patients, and these proteins may be associated with prognosis.[29]

Diagnosis

To diagnose PBC, it needs to be distinguished from other conditions with similar symptoms, such as autoimmune hepatitis or primary sclerosing cholangitis (PSC).

  • Abnormalities in liver enzyme tests are usually present and elevated gamma-glutamyl transferase and alkaline phosphatase (ALP) are found in early disease.[10] Elevations in bilirubin occur in advanced disease.
  • Antimitochondrial antibodies are the characteristic serological marker for PBC, being found in 90-95 percent of patients and only 1 percent of controls. PBC patients have AMA against pyruvate dehydrogenase complex (PDC-E2), an enzyme complex that is found in the mitochondria.[10] Those people who are AMA negative but with disease similar to PBC have been found to have AMAs when more sensitive detection methods are employed.[13]
  • Other auto-antibodies may be present:

Antinuclear antibody measurements are not diagnostic for PBC because they are not specific, but may have a role in prognosis.

Anti-glycoprotein-210 antibodies, and to a lesser degree anti-p62 antibodies, correlate with the disease's progression toward end stage liver failure. Anti-gp210 antibodies are found in 47 percent of PBC patients.[30][31]

Anti-centromere antibodies often correlate with developing portal hypertension.[32]

Anti-np62[33] and anti-sp100 are also found in association with PBC.

  • Abdominal ultrasound, MR scanning (MRCP) or a CT scan is usually performed to rule out blockage to the bile ducts. This may be needed if a condition causing secondary biliary cirrhosis, such as other biliary duct disease or gallstones, needs to be excluded. A liver biopsy may help, and if uncertainty remains as in some patients, an endoscopic retrograde cholangiopancreatography (ERCP), an endoscopic investigation of the bile duct, may be performed.

Most patients can be diagnosed without invasive investigation, as the combination of anti-mitochondrial antibodies and typical (cholestatic) liver enzyme tests are considered diagnostic. However, a liver biopsy is needed to determine the stage of disease.

Liver biopsy

On microscopic examination of liver biopsy specimens, PBC is characterized by interlobular bile duct destruction. These histopathologic findings in primary biliary cholangitis include the following:[34]

  • Inflammation of the bile ducts, characterized by intraepithelial lymphocytes, and
  • Periductal epithelioid granulomata.

Histopathology stages

  • Stage 1 – Portal Stage: Normal sized triads; portal inflammation, subtle bile duct damage. Granulomas are often detected in this stage.
  • Stage 2 – Periportal Stage: Enlarged triads; periportal fibrosis and/or inflammation. Typically characterized by the finding of a proliferation of small bile ducts.
  • Stage 3 – Septal Stage: Active and/or passive fibrous septa.
  • Stage 4 – Biliary Cirrhosis: Nodules present; garland or jigsaw puzzle pattern.

Treatment

There is no known cure, but medication may slow the progression so that a normal lifespan and quality of life may be attainable for many patients.[10][35][36]

  • Ursodeoxycholic acid (UDCA), marketed as Ursodiol and others, is the most frequently used treatment. It helps reduce the cholestasis and improves liver function tests. It has a minimal effect on symptoms and whether it improves outcomes is controversial.[37][10] A Cochrane review from 2012 did not show any significant benefits on important outcomes including mortality, liver transplantation or PBC symptoms, even if some biochemical and histological parameters were improved.[37]
  • To relieve itching caused by bile acids in circulation, which are normally removed by the liver, cholestyramine (a bile acid sequestrant) may be prescribed to absorb bile acids in the gut and be eliminated, rather than re-enter the blood stream. Other drugs that do this include stanozolol, naltrexone and rifampicin.[35][36][38]
  • Specific treatment for fatigue, which may be debilitating in some patients, is limited and undergoing trials.[39] Some studies indicate that Provigil (modafinil) may be effective without damaging the liver.[40] Though modafinil is no longer covered by patents, the limiting factor in its use in the U.S. is cost. The manufacturer, Cephalon, has made agreements with manufacturers of generic modafinil to provide payments in exchange for delaying their sale of modafinil.[41] The FTC has filed suit against Cephalon alleging anti-competitive behavior.[42]
  • People with PBC may have poor lipid-dependent absorption of Vitamins A, D, E, K.[43] Appropriate supplementation is recommended when bilirubin is elevated.[10]
  • People with PBC are at elevated risk of developing osteoporosis[44] and esophageal varices[45] as compared to the general population and others with liver disease. Screening and treatment of these complications is an important part of the management of PBC.
  • As in all liver diseases, consumption of alcohol is contraindicated.
  • In advanced cases, a liver transplant, if successful, results in a favorable prognosis.[46][47]
  • The farnesoid X receptor agonist, obeticholic acid (marketed as Ocaliva), has been licensed by various regulatory authorities, including the United States Food and Drug Administration, as an orphan drug in an accelerated approval program. Obeticholic acid, which is a modified bile acid, produced a reduction in the level of the biomarker alkaline phosphatase, a surrogate endpoint for clinical benefit in PBC.[48] It is indicated for the treatment of PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.[49] Additional studies are being undertaken to verify and describe clinical benefit.[50]
  • Other drugs that are undergoing clinical studies in UDCA non-responders include fibrates, such as fenofibrate and bezafibrate, which are pan–peroxisome proliferator–activated receptor (PPAR) agonists with anti-inflammatory and choleretic (enhanced bile secretion) effects.[51] Bezafibrate has been shown to improve biomarkers including alkaline phosphatase, but has not been licensed in PBC.[52][53]

Prognosis

The serum bilirubin level is an indicator of the prognosis of PBC, with levels of 2–6 mg/dL having a mean survival time of 4.1 years, 6–10 mg/dL having 2.1 years and those above 10 mg/dL having a mean survival time of 1.4 years.[54]

After liver transplant, the recurrence rate may be as high as 18 percent at five years, and up to 30 percent at 10 years. There is no consensus on risk factors for recurrence of the disease.[55]

Complications of PBC can be related to chronic cholestasis or cirrhosis of the liver. Chronic cholestasis leads to osteopenic bone disease and osteoporosis, alongside hyperlipidaemia and vitamin deficiencies.

Patients with PBC have an increased risk of hepatocellular carcinoma compared to the general population, as is found in other cirrhotic patients. In patients with advanced disease, one series found an incidence of 20 percent in men and 4 percent in women.[56]

Epidemiology

PBC is a chronic autoimmune liver disease with a female gender predominance with female:male ratio is at least 9:1 and a peak incidence in the fifth decade of life.[1][57] In some areas of the US and UK, the prevalence is estimated to be as high as 1 in 4000. This is much more common than in South America or Africa, which may be due to better recognition in the US and UK.[4][5] First-degree relatives may have as much as a 500 times increase in prevalence, but there is debate if this risk is greater in the same generation relatives or the one that follows.

History

In 1851, Addison and Gull described the clinical picture of progressive obstructive jaundice in the absence of mechanical obstruction of the large bile ducts.[58] Although most sources credit Ahrens with coining the term in 1950, Dauphinee and Sinclair had used the name primary biliary cirrhosis for this disease in 1949.[6] The association with anti-mitochondrial antibodies was first reported in 1965[59] and their presence was recognized as a marker of early, pre-cirrhotic disease.[60]

Society and culture

Support groups

PBC Foundation

The PBC Foundation is a UK-based international charity offering support and information to people with PBC, their families and friends.[61] It campaigns for increasing recognition of the disorder, improved diagnosis and treatments, and estimates over 8000 people are undiagnosed in the UK.[86][62] The Foundation has supported research into PBC including the development of the PBC-40 quality of life measure published in 2004[63] and helped establish the PBC Genetics Study.[20][64] It was founded by Collette Thain in 1996, after she was diagnosed with the condition.[65] Thain was awarded an MBE Order of the British Empire in 2004 for her work with the Foundation.[66] The PBC Foundation helped initiate the name change campaign in 2014.[7][8][67]

PBCers Organization

The PBCers Organization is a US-based non-profit patient support group that was founded in 1996 and advocates for greater awareness of the disease and new treatments.[68] It has supported the initiative for a change in name.[8]

Name

In 2014 the PBC Foundation, with the support of the PBCers Organization, the PBC Society (Canada)[69] and other patient groups, advocated a change in name from "primary biliary cirrhosis" to "primary biliary cholangitis," noting that most PBC patients did not have cirrhosis and that "cirrhosis" often had negative connotations of alcoholism.[7][8][67] Patient and professional groups were canvassed.[102] Support for the name change came from professional bodies including the American Association for the Study of Liver Diseases[70] and the European Association for the Study of the Liver.[104] Advocates for the name change published calls to adopt the new name in multiple hepatology journals in the fall of 2015.[71][72][73][74]

References

1. ^1 2 3 {{cite journal |vauthors=Poupon R |title=Primary Biliary Cirrhosis: A 2010 Update |journal=Journal of Hepatology |volume=52 |issue=5 |pages=745–758 |year=2010 |pmid=20347176 |doi=10.1016/j.jhep.2009.11.027 |url=}}
2. ^1 2 {{cite journal | vauthors = Hirschfield GM, Gershwin ME | title = The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis | journal = Annual Review of Pathology | volume = 8 | pages = 303–330 | date = January 2013 | pmid = 23347352 | doi = 10.1146/annurev-pathol-020712-164014 }}
3. ^{{cite book |first=Henryk |last=Dancygier |title=Principles and Practice of Clinical Hepatology|url=https://books.google.com/?id=lrPX8C4p90QC&pg=PA895 |accessdate=29 June 2010 |year=2010 |publisher=Springer |isbn=978-3-642-04509-7 |pages=895–}}
4. ^1 {{cite journal |vauthors=Boonstra K, Beuers U, Ponsioen CY |title=Epidemiology of Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis: A Systematic Review |journal=Journal of Hepatology |volume=56 |issue=5 |pages=1181–1188 |year=2012 |pmid=22245904 |doi=10.1016/j.jhep.2011.10.025 |url=}}
5. ^1 {{cite journal |vauthors=James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV |title=Primary Biliary Cirrhosis Once Rare, Now Common in the United Kingdom? |journal=Hepatology |volume=30 |issue=2 |pages=390–394 |year=1999 |pmid=10421645 |doi=10.1002/hep.510300213 |url= | displayauthors = 3 }}
6. ^1 {{cite journal|last1=Dauphinee|first1=James A.|last2=Sinclair|first2=Jonathan C.|title=Primary Biliary Cirrhosis|journal=Canadian Medical Association Journal|date=July 1949|volume=61|issue=1|pages=1–6|pmid=18153470|pmc=1591584}}
7. ^1 2 {{cite web|last1=PBC Foundation (UK)|title=PBC Name Change|url=https://www.pbcfoundation.org.uk/news/collettes-blog/pbc-name-change|accessdate=27 Jan 2017}}
8. ^1 2 3 {{cite web |last=PBCers Organization |title=Primary Biliary Cirrhosis Name Change Initiative |url=http://pbcers.org/education/NameChange1-3.pdf }}
9. ^1 2 3 {{cite journal |vauthors=Selmi C, Bowlus CL, Gershwin LE, Coppel RL | title=Primary Biliary Cirrhosis | journal=Lancet | date=7 May 2011 | volume=377 | issue=9777 | pages=1600–1609 | pmid=21529926 | doi=10.1016/S0140-6736(10)61965-4}}
10. ^1 2 3 4 5 6 {{cite journal | vauthors = Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ | title = Primary Biliary Cirrhosis | journal = Hepatology | volume = 50 | issue = 1 | pages = 291–308 | date = July 2009 | pmid = 19554543 | doi = 10.1002/hep.22906| quote = The AASLD Practice Guideline | displayauthors = 3 }}
11. ^1 {{cite journal|vauthors=Webb GJ, Siminovitch KA, Hirschfield GM | title=The Immunogenetics of Primary Biliary Cirrhosis: A Comprehensive Review | journal=Journal of Autoimmunity | year= 2015 | volume= 64| issue= | pages= 42–52| pmid=26250073 | doi=10.1016/j.jaut.2015.07.004 | pmc= 5014907}}
12. ^{{cite journal | vauthors = Saxena R, Theise N | title = Canals of Hering: Recent Insights and Current Knowledge | journal = Seminars in Liver Disease | volume = 24 | issue = 1 | pages = 43–48 | date = February 2004 | pmid = 15085485 | doi = 10.1055/s-2004-823100 }}
13. ^1 {{cite journal |pmid=15062200 | doi=10.1016/S1089-3261(03)00132-6 | volume=8 | issue=1 | title=Primary Biliary Cirrhosis and Autoimmune Cholangiopathy | year=2004 | journal=Clinical Liver Disease | pages=177–194 | vauthors=Vierling JM}}
14. ^1 2 {{cite journal | vauthors = Floreani A, Franceschet I, Cazzagon N | title = Primary Biliary Cirrhosis: Overlaps with Other Autoimmune Disorders | journal = Seminars in Liver Disease | volume = 34 | issue = 3 | pages = 352–360 | date = August 2014 | pmid = 25057958 | doi = 10.1055/s-0034-1383734 }}
15. ^{{cite journal | vauthors = Watt FE, James OF, Jones DE | title = Patterns of Autoimmunity in Primary Biliary Cirrhosis Patients and Their Families: a Population-Based Cohort Study | journal = Quarterly Journal of Medicine | volume = 97 | issue = 7 | pages = 397–406 | date = July 2004 | pmid = 15208427 | doi = 10.1093/qjmed/hch078}}
16. ^{{cite journal| vauthors=Narciso-Schiavon JL, Schiavon LL| title=To screen or not to screen? Celiac antibodies in liver diseases. | journal=World J Gastroenterol | year= 2017 | volume= 23 | issue= 5 | pages= 776–791 | pmid=28223722 | doi=10.3748/wjg.v23.i5.776 | type= Review | pmc=5296194}}{{free access}}
17. ^{{cite journal | vauthors = Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, Linares A, Veronesi L, Fuentes D, Zauli D, Bianchi FB | title = Celiac Disease in Autoimmune Cholestatic Liver disorders | journal = The American Journal of Gastroenterology | volume = 97 | issue = 10 | pages = 2609–2613 | date = October 2002 | pmid = 12385447 | doi = 10.1111/j.1572-0241.2002.06031.x | displayauthors = 3 }}
18. ^{{cite journal | vauthors = Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD, Mason AL, Myers RP, Peltekian KM, Ghent CN, Coltescu C, Atkinson EJ, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA | title = Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants | journal = The New England Journal of Medicine | volume = 360 | issue = 24 | pages = 2544–2555 | date = June 2009 | pmid = 19458352 | pmc = 2857316 | doi = 10.1056/NEJMoa0810440 | displayauthors = 3 }}
19. ^{{Cite web | url=http://www.uk-pbc.com | title=UK-PBC – Stratified Medicine in Primary Biliary Cholangitis (PBC; formally know as Cirrhosis)}}
20. ^1 {{cite journal | vauthors = Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, Ducker SJ, Day DB, Heneghan MA, Neuberger JM, Donaldson PT, Bathgate AJ, Burroughs A, Davies MH, Jones DE, Alexander GJ, Barrett JC, Sandford RN, Anderson CA | title = Dense Fine-Mapping Study Identifies New Susceptibility Loci for Primary Biliary Cirrhosis | journal = Nature Genetics | volume = 44 | issue = 10 | pages = 1137–1141 | date = October 2012 | pmid = 22961000 | pmc = 3459817 | doi = 10.1038/ng.2395 | displayauthors = 3 }}
21. ^{{cite journal | vauthors = Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, deAndrade M, Amos CI, Lazaridis KN, Seldin MF, Siminovitch KA | title = Immunochip Analyses Identify a Novel Risk Locus for Primary Biliary Cirrhosis at 13q14, Multiple Independent Associations at Four Established Risk Loci and Epistasis Between 1p31 and 7q32 Risk Variants | journal = Human Molecular Genetics | volume = 21 | issue = 23 | pages = 5209–5221 | date = December 2012 | pmid = 22936693 | pmc = 3490520 | doi = 10.1093/hmg/dds359 | url = http://hmg.oxfordjournals.org/content/early/2012/08/29/hmg.dds359.long | displayauthors = 3 }}
22. ^Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H7, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H9, Zeniya M10, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M (2019) POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. Sci Rep 9(1):102
23. ^{{cite journal | vauthors = Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME | title = Patients with Primary Biliary Cirrhosis React Against a Ubiquitous Xenobiotic-Metabolizing Bacterium | journal = Hepatology | volume = 38 | issue = 5 | pages = 1250–1257 | date = November 2003 | pmid = 14578864 | doi = 10.1053/jhep.2003.50446 | displayauthors = 3 }}
24. ^{{cite journal | vauthors = Mohammed JP, Mattner J | title = Autoimmune Disease Triggered by Infection with Alphaproteobacteria | journal = Expert Review of Clinical Immunology | volume = 5 | issue = 4 | pages = 369–379 | date = July 2009 | pmid = 20161124 | pmc = 2742979 | doi = 10.1586/ECI.09.23 }}
25. ^{{cite journal | vauthors = Kaplan MM | title = Novosphingobium aromaticivorans: a Potential Initiator of Primary Biliary Cirrhosis | journal = The American Journal of Gastroenterology | volume = 99 | issue = 11 | pages = 2147–2149 | date = November 2004 | pmid = 15554995 | doi = 10.1111/j.1572-0241.2004.41121.x }}
26. ^{{cite journal | vauthors = Selmi C, Gershwin ME | title = Bacteria and Human Autoimmunity: The Case of Primary Biliary Cirrhosis | journal = Current Opinion in Rheumatology | volume = 16 | issue = 4 | pages = 406–410 | date = July 2004 | pmid = 15201604 | doi = 10.1097/01.bor.0000130538.76808.c2 | url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1040-8711&volume=16&issue=4&spage=406 }}
27. ^{{cite journal | vauthors = Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, Scanlon ST, Pendem K, Teyton L, Hart J, Ridgway WM, Wicker LS, Gershwin ME, Bendelac A | title = Liver Autoimmunity Triggered by Microbial Activation of Natural Killer T Cells | journal = Cell Host & Microbe | volume = 3 | issue = 5 | pages = 304–315 | date = May 2008 | pmid = 18474357 | pmc = 2453520 | doi = 10.1016/j.chom.2008.03.009 | url = http://linkinghub.elsevier.com/retrieve/pii/S1931-3128(08)00120-0 | displayauthors = 3 }}
28. ^{{cite journal | vauthors = Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, Todd JA, Peterson LB, Savage PB, Wills-Karp M, Ridgway WM, Wicker LS, Mattner J | title = Identification of Cd101 as a Susceptibility Gene for Novosphingobium aromaticivorans-induced Liver Autoimmunity | journal = Journal of Immunology | volume = 187 | issue = 1 | pages = 337–349 | date = July 2011 | pmid = 21613619 | pmc = 3134939 | doi = 10.4049/jimmunol.1003525 | displayauthors = 3 }}
29. ^{{cite journal | vauthors = Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, Koyabu M, Matsuyama M, Mori T, Kamihira T, Daikoku M, Migita K, Yatsuhashi H, Nozaki N, Shimoda S, Ishibashi H | title = Increased expression of Nuclear Envelope gp210 Antigen in Small Bile Ducts in Primary Biliary Cirrhosis | journal = Journal of Autoimmunity | volume = 26 | issue = 2 | pages = 138–145 | date = March 2006 | pmid = 16337775 | doi = 10.1016/j.jaut.2005.10.007 | displayauthors = 3 }}
30. ^{{cite journal |vauthors=Nickowitz RE, Worman HJ | title = Autoantibodies From Patients With Primary Biliary Cirrhosis Recognize a Restricted Region Within the Cytoplasmic Tail of Nuclear Pore Membrane Glycoprotein Gp210 | journal = Journal of Experimental Medicine | volume = 178 | issue = 6 | pages = 2237–2242 | year = 1993 | pmid = 7504063 | doi = 10.1084/jem.178.6.2237| pmc = 2191303 }}
31. ^{{cite journal |vauthors=Bauer A, Habior A | title = Measurement of gp210 Autoantibodies in sera of Patients With Primary Biliary cirrhosis | journal = Journal of Clinical Laboratory Analysis | volume = 21 | issue = 4 | pages = 227–231 | year = 2007 | pmid = 17621358 | doi = 10.1002/jcla.20170}}
32. ^{{cite journal | vauthors = Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, Saoshiro T, Harada H, Sodeyama T, Hayashi S, Masumoto A, Sando T, Yamamoto T, Sakai H, Kobayashi M, Muro T, Koga M, Shums Z, Norman GL, Ishibashi H | title = Anti-gp210 and Anti-Centromere Antibodies Are Different Risk Factors for the Progression of Primary Biliary Cirrhosis | journal = Hepatology | volume = 45 | issue = 1 | pages = 118–127 | date = January 2007 | pmid = 17187436 | doi = 10.1002/hep.21472 | displayauthors = 3 }}
33. ^{{cite journal | vauthors = Nesher G, Margalit R, Ashkenazi YJ | title = Anti-Nuclear Envelope Antibodies: Clinical Associations | journal = Seminars in Arthritis and Rheumatism | volume = 30 | issue = 5 | pages = 313–320 | date = April 2001 | pmid = 11303304 | doi = 10.1053/sarh.2001.20266 }}
34. ^{{cite journal | vauthors = Nakanuma Y, Tsuneyama K, Sasaki M, Harada K | title = Destruction of Bile Ducts in Primary Biliary Cirrhosis | journal = Baillière's Best Practice & Research. Clinical Gastroenterology | volume = 14 | issue = 4 | pages = 549–570 | date = August 2000 | pmid = 10976014 | doi = 10.1053/bega.2000.0103 | displayauthors = 3 }}
35. ^1 {{cite journal | vauthors = Levy C, Lindor KD | title = Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis | journal = Current Treatment Options in Gastroenterology | volume = 6 | issue = 2 | pages = 93–103 | date = April 2003 | pmid = 12628068 | doi = 10.1007/s11938-003-0010-0 }}
36. ^1 {{cite journal | vauthors = Oo YH, Neuberger J | title = Options for treatment of primary biliary cirrhosis | journal = Drugs | volume = 64 | issue = 20 | pages = 2261–2271 | year = 2004 | pmid = 15456326 | doi = 10.2165/00003495-200464200-00001 }}
37. ^1 {{Cite journal|last=Rudic|first=Jelena S.|last2=Poropat|first2=Goran|last3=Krstic|first3=Miodrag N.|last4=Bjelakovic|first4=Goran|last5=Gluud|first5=Christian|date=2012-12-12|title=Ursodeoxycholic acid for primary biliary cirrhosis|journal=The Cochrane Database of Systematic Reviews|volume=12|pages=CD000551|doi=10.1002/14651858.CD000551.pub3|issn=1469-493X|pmid=23235576}}
38. ^{{cite journal | vauthors = Walt RP, Daneshmend TK, Fellows IW, Toghill PJ | title = Effect of Stanozolol on Itching in Primary Biliary Cirrhosis | journal = British Medical Journal | volume = 296 | issue = 6622 | pages = 607 | date = February 1988 | pmid = 3126923 | pmc = 2545238 | doi = 10.1136/bmj.296.6622.607}}
39. ^{{cite journal | vauthors = Abbas G, Jorgensen RA, Lindor KD | title = Fatigue in Primary Biliary Cirrhosis | journal = Nature Reviews Gastroenterology & Hepatology | volume = 7 | issue = 6 | pages = 313–319 | date = June 2010 | pmid = 20458334 | doi = 10.1038/nrgastro.2010.62 }}
40. ^Modafinil#Primary biliary cirrhosis
{{cite journal | vauthors = Ian Gan S, de Jongh M, Kaplan MM | title = Modafinil in the Treatment of Debilitating Fatigue in Primary Biliary Cirrhosis: A Clinical Experience | journal = Digestive Diseases and Sciences | volume = 54 | issue = 10 | pages = 2242–2246 | date = October 2009 | pmid = 19082890 | doi = 10.1007/s10620-008-0613-3 }}
{{cite journal | vauthors = Kumagi T, Heathcote EJ | title = Primary Biliary Cirrhosis | journal = Orphanet Journal of Rare Diseases | volume = 3 | page = 1 | year = 2008 | pmid = 18215315 | pmc = 2266722 | doi = 10.1186/1750-1172-3-1 | quote = Ref 157 viz: }}
{{cite journal | vauthors = Jones DE, Newton JL | title = An Open Study of Modafinil for the Treatment of Daytime Somnolence and Fatigue in Primary Biliary Cirrhosis | journal = Alimentary Pharmacology & Therapeutics | volume = 25 | issue = 4 | pages = 471–476 | date = February 2007 | pmid = 17270003 | doi = 10.1111/j.1365-2036.2006.03223.x }}
41. ^Modafinil#Patent protection and antitrust litigation
{{cite journal |author=Carrier MA |title=Provigil: A Case Study of Anticompetitive Behavior |journal=Hastings Science & Technology Law Journal |volume=3 |issue=2 |pages=441–452 |year=2011 |url=http://hstlj.org/content/vol3/iss2/v3i2carrier.pdf }}
42. ^{{cite web | url = http://www.ftc.gov/os/caselist/0610182/080213complaint.pdf | title = Cephalon, Inc. | publisher = Federal Trade Commission | format = | website = | accessdate = | date = 2008-02-13 }}
43. ^{{cite book | first1= Bruce R. | last1 = Bacon | first2=John G. | last2 = O'Grady | title = Comprehensive Clinical Hepatology|url=https://books.google.com/?id=ec0G9HGiR8MC&pg=PA283 | accessdate = 29 June 2010 | year = 2006 | publisher = Elsevier Health Sciences | isbn = 978-0-323-03675-7 | pages = 283– | name-list-format = vanc }}
44. ^{{cite journal | vauthors = Collier JD, Ninkovic M, Compston JE | title = Guidelines on the Management of Osteoporosis Associated with Chronic Liver Disease | journal = Gut | volume = 50 Suppl 1 | issue = Suppl 1 | pages = i1–9 | date = February 2002 | pmid = 11788576 | pmc = 1867644 | doi = 10.1136/gut.50.suppl_1.i1 }}
45. ^{{cite journal | vauthors = Ali AH, Sinakos E, Silveira MG, Jorgensen RA, Angulo P, Lindor KD | title = Varices in Early Histological Stage Primary Biliary Cirrhosis | journal = Journal of Clinical Gastroenterology | volume = 45 | issue = 7 | pages = e66–71 | date = August 2011 | pmid = 20856137 | doi = 10.1097/MCG.0b013e3181f18c4e | displayauthors = 3 }}
46. ^{{cite book |last1=Clavien |first1=Pierre-Alain |last2=Killenberg |first2=Paul G. |title=Medical Care of the Liver Transplant Patient: Total Pre-, Intra- and Post-Operative Management |publisher=Wiley-Blackwell |year=2006 |page=155 |isbn=978-1-4051-3032-5 |ref=harv | name-list-format = vanc }}
47. ^{{cite journal | vauthors = Kaneko J, Sugawara Y, Tamura S, Aoki T, Hasegawa K, Yamashiki N, Kokudo N | title = Long-Term Outcome of Living Donor Liver Transplantation for Primary Biliary Cirrhosis | journal = Transplant International | volume = 25 | issue = 1 | pages = 7–12 | date = January 2012 | pmid = 21923804 | doi = 10.1111/j.1432-2277.2011.01336.x | displayauthors = 3 }}
48. ^{{cite journal | vauthors = Ali AH, Carey EJ, Lindor KD | title = Recent Advances in the Development of Farnesoid X Receptor Agonists | journal = Annals of Translational Medicine | volume = 3 | issue = 1 | page = 5 | date = January 2015 | pmid = 25705637 | pmc = 4293481 | doi = 10.3978/j.issn.2305-5839.2014.12.06 }}
49. ^{{cite web|title=Package Insert for Ocaliva|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf|website=fda.gov|publisher=Intercept Pharmaceuticals|accessdate=15 November 2016}}
50. ^{{cite web|last1=Egan|first1=Amy G.(Deputy Director, Center for Drug Evaluation and Research)|title=Letter from Food and Drug Administration to Intercept Pharmaceuticals|url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207999Orig1s000ltr.pdf|website=fda.gov|publisher=Food and Drug Administration|accessdate=15 November 2016}}
51. ^{{cite journal |last1=Suraweera |first1=D |last2=Rahal |first2=H |last3=Jimenez |first3=M |last4=Viramontes |first4=M |last5=Choi |first5=G |last6=Saab |first6=S |title=Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. |journal=Liver International|date=December 2017 |volume=37 |issue=12 |pages=1877–1886 |doi=10.1111/liv.13477 |pmid=28517369}}
52. ^{{cite journal |last1=Levy |first1=C |last2=Lindor |first2=KD |title=Editorial: Itching to Know: Role of Fibrates in PBC. |journal=The American Journal of Gastroenterology |date=January 2018 |volume=113 |issue=1 |pages=56–57 |doi=10.1038/ajg.2017.432 |pmid=29311728}}
53. ^{{cite journal |last1=Carey |first1=Elizabeth J. |title=Progress in Primary Biliary Cholangitis |journal=New England Journal of Medicine |date=7 June 2018 |volume=378 |issue=23 |pages=2234–2235 |doi=10.1056/NEJMe1804945|pmid=29874531 }}
54. ^{{EMedicine|article|171117|Primary Biliary Cirrhosis|followup}}
55. ^{{harvnb|Clavien|Killenberg|2006|p=429}}
56. ^{{cite journal | vauthors = Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF | title = Hepatocellular Carcinoma in Primary Biliary Cirrhosis and Its Impact on Outcomes | journal = Hepatology | volume = 26 | issue = 5 | pages = 1138–1142 | date = November 1997 | pmid = 9362353 | doi = 10.1002/hep.510260508 | displayauthors = 3 }}
57. ^{{cite journal | vauthors = Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H | title = Predictive Scores in Primary Biliary Cirrhosis: A Retrospective Single Center Analysis of 204 Patients | journal = Journal of Clinical Gastroenterology | volume = 49 | issue = 5 | pages = 438–447 | date = 2014 | pmid = 25014239 | doi = 10.1097/MCG.0000000000000176 | displayauthors = 3 }}
58. ^{{cite journal| author=Reuben A| title=The serology of the Addison-Gull syndrome. | journal=Hepatology | year= 2003 | volume= 37 | issue= 1 | pages= 225–8 | pmid=12500211 | doi=10.1002/hep.510370134 | pmc= }}
59. ^{{cite journal | vauthors = Walker JG, Doniach D, Roitt IM, Sherlock S | title = Serological Tests in Diagnosis of Primary Biliary Cirrhosis | journal = Lancet | volume = 1 | issue = 7390 | pages = 827–31 | date = April 1965 | pmid = 14263538 | doi=10.1016/s0140-6736(65)91372-3}}
60. ^{{cite journal | vauthors = Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF | title = Positive Antimitochondrial Antibody but Normal Alkaline Phosphatase: Is this Primary Biliary Cirrhosis? | journal = Hepatology | volume = 6 | issue = 6 | pages = 1279–1284 | year = 1986 | pmid = 3793004 | doi = 10.1002/hep.1840060609 | displayauthors = 3 }}
61. ^{{cite web|last1=Association of Medical Research Charities|title=The PBC Foundation|url=http://www.amrc.org.uk/our-members/member-directory/the-pbc-foundation|accessdate=12 July 2015}}
62. ^{{cite journal|author= Thain, Collette |journal = At Home Magazine| format = online | year = 2015 | title=Primary Biliary Cirrhosis: Getting a Diagnosis|url=http://www.athomemagazine.co.uk/primary-biliary-cirrhosis-getting-a-diagnosis/|accessdate=28 July 2015}}
63. ^{{cite journal | vauthors = Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE | title = Development, Validation, and Evaluation of the PBC-40, a Disease Specific Health-Related Quality of Life Measure for Primary Biliary Cirrhosis | journal = Gut | volume = 54 | issue = 11 | pages = 1622–1629 | date = November 2005 | pmid = 15961522 | pmc = 1774759 | doi = 10.1136/gut.2005.065862 | displayauthors = 3 }}
64. ^{{cite journal | vauthors = Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, Ducker SJ, Muriithi AW, Wheater EF, Hammond CJ, Dawwas MF, Jones DE, Peltonen L, Alexander GJ, Sandford RN, Anderson CA | title = Genome-Wide Association study Identifies 12 New Susceptibility Loci for Primary Biliary Cirrhosis | journal = Nature Genetics | volume = 43 | issue = 4 | pages = 329–332 | date = April 2011 | pmid = 21399635 | pmc = 3071550 | doi = 10.1038/ng.789 | displayauthors = 3 }}
65. ^1 Staff of The Scotsman, January 3, 2008. Dealing with a silent killer
66. ^Barry Gordon for The Scotsman. 31 December 2003 A royal seal of approval
67. ^1 {{cite web|last1=PBC Foundation|title=EASL Name Change Presentation|url=http://www.pbcfoundation.org.uk/Home/BlogItem/12|accessdate=8 July 2015}}
68. ^{{cite web|last1=Kim|first1=Margot|title=New hope for PBC liver disease|url=http://abc30.com/health/new-hope-for-pbc-liver-disease/479448/|website=ABC30 Action news|accessdate=4 August 2015|date=2015-01-18}}
69. ^{{cite journal |vauthors=Cheung AC, Montano-Loza A, Swain M, Vincent C, Renner E, Sherman M, Janssen H, Mason AL |title=Time to Make the Change from 'Primary Biliary Cirrhosis' to 'Primary Biliary Cholangitis' |journal=Canadian Journal of Gastroenterology and Hepatology |volume=29 |issue=6 |page=293 |year=2015 |pmid=26196152 |doi= 10.1155/2015/764684| displayauthors = 3 |pmc=4578449}}
70. ^{{cite web|last1=AASLD|title=A Name Change for PBC: Cholangitis Replacing Cirrhosis|url=https://www.aasld.org/name-change-pbc-cholangitis-replacing-cirrhosis|accessdate=6 July 2015}}
71. ^{{cite journal |vauthors=Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R |title=Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis' |journal=Hepatology |volume= 62|issue= 5|pages= 1620–1622|year=2015 |pmid=26372460 |doi=10.1002/hep.28140 |url= | displayauthors = 3 }}
72. ^1 {{cite journal |vauthors=Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R |title=Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis' |journal=Gut |volume= 64|issue= 11|pages= 1671–1672|year=2015 |pmid=26374822 |doi=10.1136/gutjnl-2015-310593 |url= | displayauthors = 3 }}
73. ^1 {{cite journal |vauthors=Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R |title=Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis' |journal=Journal of Hepatology |volume= 63|issue= 5|pages= 1285–1287|year=2015 |pmid=26385765 |doi=10.1016/j.jhep.2015.06.031 |url= | displayauthors = 3 }}
74. ^{{cite journal |vauthors=Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R |title=Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis' |journal=Gastroenterology |volume= 149|issue= 6|pages= 1627–1629|year=2015 |pmid=26385706 |doi=10.1053/j.gastro.2015.08.031 |url= | displayauthors = 3 }}

External links

{{Medical resources
| DiseasesDB = 10615
| ICD10 = {{ICD10|K|74|3|k|70}}
| ICD9 = {{ICD9|571.6}}
| ICDO =
| OMIM = 109720
| MedlinePlus = 000282
| eMedicineSubj = med
| eMedicineTopic = 223
| MeshID = D008105
}}
  • Primary Biliary Cirrhosis page from the National Digestive Diseases Information Clearinghouse
{{Gastroenterology}}

5 : Diseases of liver|Hepatology|Autoimmune diseases|Biliary tract disorders|Articles containing video clips
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/11 13:54:18